Overview
VENUS MEDTECH-B (2500)
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Ma...
- Open
- 1.000
- High
- 1.000
- Low
- 0.970
- Prev. Close
- 0.990
- Volume
- 733.50K
- Turnover
- 726.30K
- Avg Price
- 0.990
- Bid/Ask Ratio
- -66.07%
- Amplitude
- 3.03%
- 52wk High
- 3.860
- Volume Ratio
- 0.91
- Turnover Ratio
- 0.17%
- 52wk Low
- 0.940
- HK Mkt Cap
- 436.60M
- Market CapHKD
- 436.60M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.21
- EPSDynamic
- -0.999
- EPSStatic
- --
- BVPS
- 3.98
- P/B
- 0.25
- HK Shares
- 441.01M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 441.01M
- Min lot size
- 500
- Currency
- HKD
VENUS MEDTECH-B Analyst Rating
View moreForecast & Rating
Nov 11, 2025Daily Events
- Jul, 3
Venus Medtech surged 28.2% in heavy volume to close at HKD 1.73, driven by Cardiovalve CE marking submission and completion of the 150-patient TARGET study enrollment. The stock opened at HKD 1.27, rallied to an intraday high of HKD 1.82 before paring gains, resulting in a 42.5% daily range. Despite a 48% YoY revenue decline to HKD 66.5 million, net loss per share improved 44% to HKD -0.35. The stock now trades 63% above its 52-week low of HKD 1.06 and sits above both the 20-day (HKD 1.27) and 60-day (HKD 1.59) moving averages, though still 69% below the 52-week high of HKD 5.47. Year-to-date the stock is down 30%, while the company has divested a Hangzhou industrial property and a minority investment totaling approximately HKD 525 million to refocus on its valve business.
News
Market Movers · Venus Medtech surges 13% in Hong Kong trading
Market Movers · Venus Medtech climbs 6% in Hong Kong trading
Global Report · Biotech Breakthroughs vs Governance Scandals: Hong Kong's Niche Stock Divide
Global Report · Why Hong Kong's Small Caps Are Priced by Deals, Not Products
Global Report · Beyond the Noise: How Hong Kong's 'Other' Stocks Are Winning Through Quiet Reinvention
